US7256257B2
(en)
*
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
US6884869B2
(en)
*
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
EP1448588A4
(de)
|
2001-10-23 |
2006-10-25 |
Psma Dev Company L L C |
Psma-antikörper und proteinmultimere
|
US20040161776A1
(en)
|
2001-10-23 |
2004-08-19 |
Maddon Paul J. |
PSMA formulations and uses thereof
|
ES2544527T3
(es)
|
2002-07-31 |
2015-09-01 |
Seattle Genetics, Inc. |
Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
|
JP5356648B2
(ja)
|
2003-02-20 |
2013-12-04 |
シアトル ジェネティックス, インコーポレイテッド |
抗cd70抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
|
ZA200603619B
(en)
|
2003-11-06 |
2008-10-29 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
DE602005022928D1
(de)
|
2004-11-30 |
2010-09-23 |
Abgenix Inc |
Antikörper gegen gpnmb und ihre verwendungen
|
CN101203241B
(zh)
|
2005-04-19 |
2012-02-22 |
西雅图基因公司 |
人源化抗-cd70结合物和其应用
|
LT1912671T
(lt)
|
2005-07-18 |
2017-12-11 |
Seattle Genetics, Inc. |
Vaisto konjugatai, turintys gliukoronido linkerį
|
US7910108B2
(en)
*
|
2006-06-05 |
2011-03-22 |
Incyte Corporation |
Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
|
EP2064350B1
(de)
|
2006-11-27 |
2013-01-02 |
Ludwig Institute for Cancer Research Ltd. |
Expression von foxp3 durch krebszellen
|
ES2523915T5
(es)
|
2006-12-01 |
2022-05-26 |
Seagen Inc |
Agentes de unión a la diana variantes y usos de los mismos
|
EP2377952A1
(de)
|
2007-04-26 |
2011-10-19 |
Ludwig Institute For Cancer Research |
Verfahren zur Diagnostizierung und Behandlung von Astrozytoma
|
US9845355B2
(en)
|
2007-07-16 |
2017-12-19 |
Genentech, Inc. |
Humanized anti-CD79b antibodies and immunoconjugates and methods of use
|
PL2474557T3
(pl)
|
2007-07-16 |
2015-02-27 |
Genentech Inc |
Przeciwciała anty- CD79b i immunokoniugaty i sposoby stosowania
|
WO2009046407A2
(en)
|
2007-10-04 |
2009-04-09 |
Zymogenetics, Inc. |
B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
|
US7892760B2
(en)
|
2007-11-19 |
2011-02-22 |
Celera Corporation |
Lung cancer markers, and uses thereof
|
BRPI0907046A2
(pt)
|
2008-01-18 |
2015-07-28 |
Medimmune Llc |
Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
|
RU2553566C2
(ru)
|
2008-01-31 |
2015-06-20 |
Дженентек, Инк. |
АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
JP5624535B2
(ja)
|
2008-05-02 |
2014-11-12 |
シアトル ジェネティクス,インコーポレーテッド |
低いコアフコシル化を有する抗体及び抗体誘導体を調製するための方法並びに組成物
|
EP2727606A3
(de)
|
2008-09-08 |
2015-09-23 |
Psma Development Company, L.L.C. |
Verbindungen zur tötung von psma-expriemierenden und taxane-resistenten krebszellen
|
EP2389583A1
(de)
|
2009-01-22 |
2011-11-30 |
Ludwig Institute for Cancer Research, Ltd. |
Verfahren und zusammensetzungen zur diagnose und behandlung maligner und nichtmaligner gammopathien
|
JP5918129B2
(ja)
|
2009-06-22 |
2016-05-18 |
メディミューン,エルエルシー |
部位特異的共役のための操作されたFc領域
|
US8785600B2
(en)
|
2009-10-23 |
2014-07-22 |
Millennium Pharmaceuticals, Inc. |
Anti-GCC antibody molecules and related compositions and methods
|
EP2510011B2
(de)
|
2009-12-09 |
2021-03-31 |
Institut National de la Santé et de la Recherche Médicale |
B7h6 -bindende monoklonale antikörper und ihre verwendung
|
US8609092B2
(en)
|
2010-02-08 |
2013-12-17 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
|
RU2573994C2
(ru)
|
2010-02-10 |
2016-01-27 |
Иммьюноджен, Инк |
Антитела против cd20 и их применение
|
MY187990A
(en)
|
2010-03-31 |
2021-11-07 |
Boehringer Ingelheim Int |
Anti-cd40 antibodies
|
KR20130130709A
(ko)
|
2010-09-29 |
2013-12-02 |
어젠시스 인코포레이티드 |
191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(adc)
|
CN103561759B
(zh)
|
2010-10-22 |
2016-10-12 |
西雅图遗传学公司 |
以奥里斯他汀(AURISTATIN)为主的抗体药物结合物与PI3K-AKT mTOR路径抑制剂之间的协同作用
|
WO2012119091A1
(en)
|
2011-03-02 |
2012-09-07 |
Beth Israel Deaconess Medical Center, Inc. |
Mcl-1 as a therapeutic target in scffbw7 deficient neoplasm
|
WO2012148943A1
(en)
*
|
2011-04-25 |
2012-11-01 |
Arizona Board Of Regents, For And On Behalf Of, Arizona State University |
Crystal structures of dolastatin 16, dolamethylleuine and dolaphenvaline, and methods for preparing dolamethylleuine and dolaphenvaline
|
WO2012156918A1
(en)
|
2011-05-16 |
2012-11-22 |
Koninklijke Philips Electronics N.V. |
Bio-orthogonal drug activation
|
WO2012156532A1
(en)
|
2011-05-19 |
2012-11-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-human-her3 antibodies and uses thereof
|
TWI597065B
(zh)
|
2011-06-10 |
2017-09-01 |
梅爾莎納醫療公司 |
蛋白質-聚合物-藥物共軛體
|
US9409988B2
(en)
|
2011-06-22 |
2016-08-09 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-Axl antibodies and uses thereof
|
KR20140104944A
(ko)
|
2011-06-22 |
2014-08-29 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
항-axl 항체 및 그의 용도
|
EP3539982A3
(de)
|
2011-12-23 |
2020-01-15 |
Pfizer Inc |
Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
|
JP2015505537A
(ja)
|
2012-01-20 |
2015-02-23 |
シー レーン バイオテクノロジーズ, エルエルシー |
結合分子コンジュゲート
|
WO2013159035A2
(en)
|
2012-04-19 |
2013-10-24 |
Medical College Of Wisconsin, Inc. |
Highly sensitive surveillance using detection of cell free dna
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
US9522940B2
(en)
|
2012-05-23 |
2016-12-20 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
|
PL2859017T3
(pl)
|
2012-06-08 |
2019-07-31 |
Sutro Biopharma, Inc. |
Przeciwciała zawierające swoiste dla miejsca, niewystępujące naturalnie reszty aminokwasowe, sposoby ich wytwarzania i sposoby ich zastosowania
|
JP6343609B2
(ja)
|
2012-06-19 |
2018-06-13 |
アンブルックス, インコーポレイテッドAmbrx, Inc. |
抗cd70抗体薬物複合体
|
EP3135690A1
(de)
|
2012-06-26 |
2017-03-01 |
Sutro Biopharma, Inc. |
Modifizierte fc-proteine mit stellenspezifischen nichtnatürlichen aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
|
KR102355959B1
(ko)
|
2012-08-23 |
2022-01-27 |
어젠시스 인코포레이티드 |
158p1d7 단백질에 결합하는 항체 약물 컨쥬게이트(adc)
|
CN104981254B
(zh)
|
2012-08-31 |
2018-05-22 |
苏特罗生物制药公司 |
含有叠氮基的经修饰的氨基酸
|
WO2014081303A1
(en)
|
2012-11-22 |
2014-05-30 |
Tagworks Pharmaceuticals B.V. |
Chemically cleavable group
|
ES2701076T3
(es)
|
2012-11-24 |
2019-02-20 |
Hangzhou Dac Biotech Co Ltd |
Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
|
WO2014093394A1
(en)
|
2012-12-10 |
2014-06-19 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
EP2931316B1
(de)
|
2012-12-12 |
2019-02-20 |
Mersana Therapeutics, Inc. |
Hydroxylpolymer-heilmittelproteinkonjugate
|
KR20150132864A
(ko)
|
2013-03-15 |
2015-11-26 |
애브비 인코포레이티드 |
항체 약물 접합체(adc) 정제
|
RU2020125266A
(ru)
|
2013-03-15 |
2020-09-24 |
Эббви Дойчланд Гмбх Унд Ко. Кг |
Составы конъюгата антитело против egfr-лекарственное средство
|
ES2865473T3
(es)
|
2013-07-10 |
2021-10-15 |
Sutro Biopharma Inc |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
RU2679657C2
(ru)
|
2013-08-01 |
2019-02-12 |
Эдженсис, Инк. |
Конъюгаты антител с лекарственными средствами, связывающиеся с белками cd37
|
AU2014318545A1
(en)
|
2013-09-12 |
2016-03-24 |
Halozyme, Inc. |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
EP3055298B1
(de)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modifizierte aminosäuren mit funktionellen tetrazingruppen, verfahren zur herstellung und verfahren zu deren verwendung
|
JP6502931B2
(ja)
|
2013-10-11 |
2019-04-17 |
アメリカ合衆国 |
Tem8抗体およびその使用
|
WO2015054669A1
(en)
|
2013-10-11 |
2015-04-16 |
Asana Biosciences, Llc |
Protein-polymer-drug conjugates
|
WO2015054659A1
(en)
|
2013-10-11 |
2015-04-16 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
WO2015057250A1
(en)
|
2013-10-18 |
2015-04-23 |
Psma Development Company, Llc |
Combination therapies with psma ligand conjugates
|
US9644037B2
(en)
|
2013-10-18 |
2017-05-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use
|
JP6908964B2
(ja)
|
2013-10-18 |
2021-07-28 |
ピーエスエムエー ディベロップメント カンパニー,エルエルシー |
Psmaリガンドコンジュゲートによる併用療法
|
EP3066118B1
(de)
|
2013-11-06 |
2020-01-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Alk-antikörper, konjugate und chimäre antigenrezeptoren und deren verwendung
|
ES2865196T3
(es)
|
2013-11-07 |
2021-10-15 |
Inst Nat Sante Rech Med |
Anticuerpos anti-HER3 humana alostéricos de neuregulina
|
US20150147339A1
(en)
|
2013-11-15 |
2015-05-28 |
Psma Development Company, Llc |
Biomarkers for psma targeted therapy for prostate cancer
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
EP3094350B1
(de)
|
2014-01-15 |
2020-03-04 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Auf knorpel gerichtete wirkstoffe und deren verwendung
|
CN114262344A
(zh)
|
2014-02-28 |
2022-04-01 |
杭州多禧生物科技有限公司 |
带电荷链接体及其在共轭反应上的应用
|
TW202214691A
(zh)
|
2014-03-21 |
2022-04-16 |
美商艾伯維有限公司 |
抗-egfr抗體及抗體藥物結合物
|
FR3020063A1
(fr)
|
2014-04-16 |
2015-10-23 |
Gamamabs Pharma |
Anticorps humain anti-her4
|
EP3473271B1
(de)
|
2014-07-31 |
2022-07-20 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Humane monoklonale antikörper gegen epha4 und deren verwendung
|
PL3262071T3
(pl)
|
2014-09-23 |
2020-08-10 |
F. Hoffmann-La Roche Ag |
Sposób stosowania immunokoniugatów anty-CD79b
|
WO2016130969A1
(en)
|
2015-02-13 |
2016-08-18 |
George Robert Pettit |
Silstatin compounds
|
US10301377B2
(en)
|
2015-02-24 |
2019-05-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
MX2017011380A
(es)
|
2015-03-09 |
2018-04-26 |
Agensys Inc |
Conjugados anticuerpo-farmaco (adc) que se ligan a proteinas flt3.
|
EP3091033A1
(de)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3-antikörper und verwendungen davon
|
US10591465B2
(en)
|
2015-05-12 |
2020-03-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for labeling, detection and isolation of Foxp3+ regulatory T cells, isolated population of Foxp3+ regulatory T cells thus obtained and uses thereof
|
JP6770533B2
(ja)
|
2015-05-22 |
2020-10-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Cath−Dの触媒活性と、そのLRP1レセプターへの結合との両方を阻害するヒトモノクローナル抗体フラグメント
|
WO2016189091A1
(en)
|
2015-05-26 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas
|
WO2016189118A1
(en)
|
2015-05-28 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
|
EP3845557B1
(de)
|
2015-06-12 |
2023-08-02 |
Lentigen Technology, Inc. |
Verfahren zur behandlung von krebs mit veränderten t-zellen
|
NZ739830A
(en)
|
2015-07-12 |
2021-12-24 |
Hangzhou Dac Biotech Co Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
US10392441B2
(en)
|
2015-10-07 |
2019-08-27 |
United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
|
EP3359562B1
(de)
|
2015-10-09 |
2019-12-04 |
Miltenyi Biotec Technology, Inc. |
Chimäre antigen-rezeptoren und methoden zur verwendung davon
|
US10556953B2
(en)
|
2015-10-12 |
2020-02-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction
|
EP3407917A1
(de)
|
2016-01-27 |
2018-12-05 |
Sutro Biopharma, Inc. |
Anti-cd74-antikörperkonjukate, zusammensetzungen mit anti-cd74-antikörperkonjugaten und verfahren zur verwendung von anti-cd74-antikörperkonjugaten
|
EP3419655A1
(de)
|
2016-02-27 |
2019-01-02 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Peptidimpfstoffe mit selbstanordnenden polymernanopartikeln
|
EP3791897A1
(de)
|
2016-02-29 |
2021-03-17 |
Madrigal Pharmaceuticals, Inc. |
Hsp9-inhibitor-wirkstoff-konjugate
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
CN109843919A
(zh)
|
2016-03-25 |
2019-06-04 |
西雅图基因公司 |
用于制备聚乙二醇化的药物-接头及其中间体的方法
|
WO2017190104A1
(en)
|
2016-04-29 |
2017-11-02 |
Medical College Of Wisconsin, Inc. |
Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer
|
JP2019521973A
(ja)
|
2016-06-08 |
2019-08-08 |
アッヴィ・インコーポレイテッド |
抗bh7−h3抗体及び抗体薬物コンジュゲート
|
MX2018015272A
(es)
|
2016-06-08 |
2019-08-12 |
Abbvie Inc |
Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
|
BR112018075653A2
(pt)
|
2016-06-08 |
2019-08-27 |
Abbvie Inc |
anticorpos anti-b7-h3 e conjugados anticorpo fármaco
|
LT3458479T
(lt)
|
2016-06-08 |
2021-02-25 |
Abbvie Inc. |
Anti-b7-h3 antikūnai ir antikūnų vaisto konjugatai
|
CA3027033A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
WO2018004338A1
(en)
|
2016-06-27 |
2018-01-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
JP7160482B2
(ja)
|
2016-09-02 |
2022-10-25 |
レンティジェン・テクノロジー・インコーポレイテッド |
Duocarを用いてがんを処置するための組成物および方法
|
KR20220147721A
(ko)
|
2016-11-14 |
2022-11-03 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
US10183993B2
(en)
|
2017-01-09 |
2019-01-22 |
Lentigen Technology Inc. |
Compositions and methods for treating cancer with anti-mesothelin immunotherapy
|
MX2019010769A
(es)
|
2017-03-24 |
2019-12-11 |
Seattle Genetics Inc |
Proceso para la preparacion de enlazadores de farmacos de glucuronidos y compuestos intermediarios de los mismos.
|
CN110997719B
(zh)
|
2017-03-24 |
2020-12-11 |
莱蒂恩技术公司 |
用于用抗cd33免疫疗法治疗癌症的组合物和方法
|
EP3612567A4
(de)
|
2017-04-19 |
2020-11-11 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1-antikörper und antikörper-wirkstoff-konjugate
|
TW201905037A
(zh)
|
2017-06-22 |
2019-02-01 |
美商梅爾莎納醫療公司 |
藥物攜帶聚合物支架及蛋白質聚合物藥物共軛物之製造方法
|
US20200207859A1
(en)
|
2017-07-26 |
2020-07-02 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
US10442867B2
(en)
|
2017-07-31 |
2019-10-15 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
|
CN107375338B
(zh)
*
|
2017-07-31 |
2020-08-28 |
中国医学科学院药用植物研究所海南分所 |
一种瘤背石磺提取物的制备方法和应用
|
CN111936510A
(zh)
|
2017-09-15 |
2020-11-13 |
莱蒂恩技术公司 |
用于用抗cd19免疫治疗来治疗癌症的组合物和方法
|
RU2020111503A
(ru)
|
2017-09-18 |
2021-10-20 |
Сутро Биофарма, Инк. |
Конъюгаты антитела к рецептору фолиевой кислоты альфа и их применение
|
CN111629735A
(zh)
|
2017-10-16 |
2020-09-04 |
莱蒂恩技术公司 |
用于用抗cd22免疫治疗来治疗癌症的组合物和方法
|
US11629167B2
(en)
|
2017-11-09 |
2023-04-18 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Betulastatin compounds
|
AU2018388997A1
(en)
|
2017-12-20 |
2020-07-09 |
Lentigen Technology, Inc. |
Compositions and methods for treating HIV/AIDS with immunotherapy
|
WO2019212356A1
(en)
|
2018-05-04 |
2019-11-07 |
Tagworks Pharmaceuticals B .V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
EP3788032B1
(de)
|
2018-05-04 |
2024-01-24 |
Tagworks Pharmaceuticals B.V. |
Verbindungen mit einem linker zur erhöhung der transcyclooctenstabilität
|
EA202190094A1
(ru)
|
2018-06-29 |
2021-04-21 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Антитела против cd40 для применения в лечении аутоиммунного заболевания
|
CA3104142A1
(en)
|
2018-07-11 |
2020-01-16 |
Timothy Clyde GRANADE |
Monoclonal antibody for the detection of the antiretroviral drug emtricitabine (ftc, 2',3'-dideoxy-5-fluoro-3'-thiacytidine)
|
US20220047716A1
(en)
|
2018-09-17 |
2022-02-17 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
CN113260630A
(zh)
|
2018-09-20 |
2021-08-13 |
莱蒂恩技术公司 |
用于用抗cd123免疫治疗来治疗癌症的组合物和方法
|
WO2020069184A2
(en)
|
2018-09-26 |
2020-04-02 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
EP3873534A1
(de)
|
2018-10-29 |
2021-09-08 |
Mersana Therapeutics, Inc. |
Cystein-modifizierte antikörper-wirkstoff-konjugate mit peptidhaltigen linkern
|
EP3886895A1
(de)
|
2018-11-30 |
2021-10-06 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd38-immuntherapie
|
EP3898699A1
(de)
|
2018-12-19 |
2021-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und zusammensetzungen zur behandlung von krebs durch immunmodulation unter verwendung von antikörpern gegen cathespin-d
|
JP2022524507A
(ja)
|
2019-03-06 |
2022-05-06 |
レンティジェン・テクノロジー・インコーポレイテッド |
自己駆動型キメラ抗原受容体を用いてがんを処置するための組成物および方法
|
US20220362394A1
(en)
|
2019-05-03 |
2022-11-17 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
EP3976653A1
(de)
|
2019-05-30 |
2022-04-06 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-bcma-immuntherapie
|
JP2022537543A
(ja)
|
2019-06-17 |
2022-08-26 |
タグワークス ファーマシューティカルス ビー.ブイ. |
高速で且つ効率的なクリック放出の為の化合物
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
EP3994173A1
(de)
|
2019-07-02 |
2022-05-11 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Monoklonale egfrviii-bindende antikörper und ihre verwendung
|
EP3812008A1
(de)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-kompetitiver antagonistischer antikörper
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
WO2021178597A1
(en)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
CA3171101A1
(en)
|
2020-06-22 |
2021-12-30 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
|
WO2022061061A1
(en)
|
2020-09-21 |
2022-03-24 |
Boehringer Ingelheim International Gmbh |
Use of anti-cd40 antibodies for treatment of inflammatory conditions
|
EP4240397A1
(de)
|
2020-11-05 |
2023-09-13 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd19/cd22-immuntherapie
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
CA3208365A1
(en)
|
2021-02-15 |
2022-08-18 |
Chantal KUHN |
Cell therapy compositions and methods for modulating tgf-b signaling
|
KR20240004659A
(ko)
|
2021-04-30 |
2024-01-11 |
셀진 코포레이션 |
감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법
|
WO2023278377A1
(en)
|
2021-06-29 |
2023-01-05 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
AU2022338463A1
(en)
|
2021-09-03 |
2024-03-21 |
Toray Industries, Inc. |
Pharmaceutical composition for cancer treatment and/or prevention
|
WO2023031445A2
(en)
|
2021-09-06 |
2023-03-09 |
Veraxa Biotech Gmbh |
Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
|
EP4186529A1
(de)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Verbesserte antikörper-nutzlast-konjugate (aps), hergestellt durch ortsspezifische konjugation mittels genetischer codeerweiterung
|
WO2023094525A1
(en)
|
2021-11-25 |
2023-06-01 |
Veraxa Biotech Gmbh |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
WO2023104941A1
(en)
|
2021-12-08 |
2023-06-15 |
European Molecular Biology Laboratory |
Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
|
WO2023158305A1
(en)
|
2022-02-15 |
2023-08-24 |
Tagworks Pharmaceuticals B.V. |
Masked il12 protein
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
US20240058465A1
(en)
|
2022-06-30 |
2024-02-22 |
Sutro Biopharma, Inc. |
Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
US20240075142A1
(en)
|
2022-08-26 |
2024-03-07 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy
|
WO2024080872A1
(en)
|
2022-10-12 |
2024-04-18 |
Tagworks Pharmaceuticals B.V. |
Strained bicyclononenes
|